Incontinentia pigmenti
MONDO:0010631Incontinentia pigmenti (IP) is a rare X-linked dominant multi-systemic ectodermal dysplasia usually lethal in males and presenting neonatally in females with a bullous rash along Blashko's lines (BL) followed by verrucous plaques evolving over time to hyperpigmented swirling patterns. It is further characterized by teeth abnormalities, alopecia, nail dystrophy and affects occasionally the retina and the central nervous system (CNS).
Also known as: Bloch-Siemens syndrome, Bloch-Sulzberger syndrome, Incontinentia pigmenti syndrome, incontinentia pigmenti, incontinentia pigmenti, X-linked dominant, IP, IP2 (formerly), Incontinentia pigmenti type 2 (formerly)
31 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New program aims to protect young kenyan women from both HIV and partner violence
Prevention OngoingThis study tests a program called Tu'Washindi, designed by and for young women in Kenya. It combines support clubs and community sessions to help girls ages 15-24 reduce intimate partner violence and consistently use HIV prevention pills (PrEP). About 1,562 participants will be f…
Phase: NA • Sponsor: RTI International • Aim: Prevention
Last updated Jun 27, 2026 12:04 UTC
-
AI vs. skin doctors: who diagnoses better?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether artificial intelligence (AI) can match a dermatologist's diagnosis when a general practitioner sends in photos and questions about a patient's skin condition. Researchers will compare the AI's diagnosis to the dermatologist's for about 1000 adults. The…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Free eye tests aim to catch vision loss early in harlem and washington heights
Knowledge-focused OngoingThis study offers free vision screenings to underserved adults over 40 living in affordable housing in Harlem and Washington Heights. The goal is to find eye problems like glaucoma, cataracts, and diabetic retinopathy early and connect people with follow-up care. About 749 partic…
Phase: NA • Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC